Fraud

PCRX Shareholders Invited to Spearhead Class Action Lawsuit Against Pacira BioSciences for Alleged Securities Fraud

by

Investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) are presented with a significant opportunity as the deadline approaches to apply as lead plaintiff in a securities fraud lawsuit. The case under consideration alleges misleading statements by the company, potentially impacting shareholder investments. Investors who have suffered losses connected to Pacira’s actions, particularly during the period between April 23, 2021, and August 9, 2022, are urged to step forward. The lawsuit, managed by The Schall Law Firm, a Los Angeles-based firm with expertise in securities class action and shareholder rights litigation, focuses on how the company might … Read more

Rudy Giuliani Faces Possible Contempt Ruling Over Continued Election Fraud Allegations Against Georgia Workers After $148M Defamation Loss

by

WASHINGTON — A federal court in Washington, D.C., is set to address whether Rudy Giuliani, former New York City mayor and attorney for Donald Trump, should be held in contempt for persistently casting false allegations against two Georgia election workers. This upcoming hearing follows a recent $148 million defamation judgment favoring the workers, who claim ongoing distress due to Giuliani’s actions. Attorneys for Wandrea “Shaye” Moss and her mother, Ruby Freeman, propose that U.S. District Judge Beryl Howell impose civil contempt sanctions against Giuliani for his continued unfounded claims of election fraud involving the two … Read more

Opportunity Opens for APLT Investors to Spearhead Securities Fraud Legal Action Against Applied Therapeutics, Inc.

by

Investors who have purchased shares of Applied Therapeutics, Inc. may have a significant opportunity to lead a securities fraud lawsuit against the biopharmaceutical company. Applied Therapeutics, based in New York, is currently under scrutiny for alleged misleading statements and possible fraudulent activities related to the success and regulatory status of its developmental drug candidates. The focus of the allegations centers on the company’s lead product candidate, AT-007, a central nervous system penetrant Aldose Reductase inhibitor being developed for the treatment of Galactosemia, a rare pediatric metabolic disease. Concerns were raised after discrepancies were noted between … Read more

Federal Grand Jury to Decide Fate of Real Estate Moguls Accused in Multimillion-Dollar Investment Fraud

by

A federal grand jury is delving into the affairs of LeFever Mattson, a real estate investment firm, as part of a significant investigation into alleged fraudulent activities surrounding its founders, Ken Mattson and Tim LeFever. The jury is scrutinizing a plethora of documents and testimonies to determine if there’s sufficient evidence to bring charges against the company or its key executives. The probe has revealed issues with the company’s operations, particularly that investors who backed the enterprise, once valued at $400 million, have ceased receiving dividends and cannot withdraw their funds. Court filings indicate that … Read more